For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of them
During Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine.
In an era marked by rapid technological advancements and evolving healthcare needs, the European Medicines Agencies Network Strategy 2028 stands as a key document.
At the heart of every pharma company lies a big problem: medical affairs and commercial teams are independently creating the same content.
March saw major defections, and a few hires, at US and UK government agencies, as well as a number of consultancy hires.
Editor's Picks
